chufangao/CTO huggingface dataset:
Clinical trial NCT02749227: Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
Official title: Pilot Study of Pasireotide LAR Treatment of Silent Corticotrophin Pituitary Tumors and Effects on Plasma Levels of POMC
Acronym: PASSILCORT
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of funding
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-10
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Limitations and caveats: The study was terminated due to poor enrollment.
Plan to share individual participant data: NO
Clinical trial NCT03486899: A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
Official title: A Phase 2B Randomized Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
Acronym: FALCON 1
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 197.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-06-19
Primary completion date: 2020-09-14
Completion date: 2021-08-17
Clinical trial NCT03630159: Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
Official title: Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Acronym: PORTIA
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-09
Primary completion date: 2021-07-20
Completion date: 2021-07-20
Plan to share individual participant data: NO
Clinical trial NCT03990077: Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
Official title: A Phase I , Single Arm, Dose Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
Sponsor: Shanghai Kechow Pharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: drug development strategy adjustment
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-21
Primary completion date: 2021-07-20
Completion date: 2021-07-20
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04752371: A Study to Evaluate Camoteskimab in Participants With Still's Disease
Official title: A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Camoteskimab in Subjects With Adult Onset Still's Disease
Sponsor: Apollo Therapeutics Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor discretion
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-25
Primary completion date: 2022-05-24
Completion date: 2022-05-24
Plan to share individual participant data: NO
Clinical trial NCT01420926: Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
Official title: A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients &gt;/= 60 Years Old With Acute Myeloid Leukemia (AML)
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 165.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-11-16
Primary completion date: 2016-06-05
Completion date: 2021-04-01
Baseline population: Two (2) participants never received any protocol treatment; per study design these patients were excluded from all analyses.
Clinical trial NCT05030350: Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
Official title: A Phase 3 Open-label Safety Trial of PH94B Nasal Spray in the Acute Treatment of Anxiety in Adult Subjects With Social Anxiety Disorder (SAD)
Sponsor: VistaGen Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study stopped by the sponsor for business reasons and not due to any safety concerns with PH94B
Enrollment: 483.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-10-01
Primary completion date: 2022-09-23
Completion date: 2022-09-23
Plan to share individual participant data: NO
Clinical trial NCT04091880: Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine
Official title: A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine (Split Virion),Inactivated
Sponsor: China National Biotec Group Company Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 1134.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-26
Primary completion date: 2020-01-06
Completion date: 2021-08-10
Plan to share individual participant data: NO
Clinical trial NCT03382600: Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)
Official title: A Phase IIb, Clinical Trial to Study the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as a First Line Chemotherapy in Participants With Advanced or Recurrent Gastric Cancer (KEYNOTE-659)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-26
Primary completion date: 2021-05-30
Completion date: 2021-05-30
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03870399: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
Official title: Phase II Study of Hormone Therapy With Tamoxifen in Patients With Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
Acronym: HORMONET
Sponsor: AC Camargo Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-13
Primary completion date: 2023-05-13
Completion date: 2023-05-13
Plan to share individual participant data: NO
Clinical trial NCT05044429: Postoperative Pain Control Following Renal Transplant
Official title: Postoperative Pain Control With Systemic Lidocaine vs. Regional Anesthesia in Renal Transplant Patients
Sponsor: George Washington University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of interest for continuing on by PI and issues with IRB
Enrollment: 31.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-16
Primary completion date: 2023-11-29
Completion date: 2023-11-29
Plan to share individual participant data: NO
Clinical trial NCT04978324: Scaling and Root Planning With Localized Delivery of Autogenous Growth Factors- Platelet Rich Fibrin (PRF)
Official title: Scaling and Root Planning With Localized Delivery of Autogenous Growth Factors- Platelet Rich Fibrin (PRF): A Randomized Split-mouth Clinical Trial
Sponsor: Virginia Commonwealth University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Fellow graduated before successfully enrolling any participants
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-31
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT06012565: KAND567 Versus Placebo in Subjects Hospitalized With COVID-19
Official title: KAND567 Versus Placebo in Subjects Hospitalized With COVID-19. A Phase II, Randomized, 2-Arm Parallel-Group, Double-blind Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics
Sponsor: Kancera AB (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow recruitment
Enrollment: 35.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-11
Primary completion date: 2021-08-07
Completion date: 2021-08-07
Plan to share individual participant data: NO
Clinical trial NCT03729596: MGC018 With or Without MGA012 in Advanced Solid Tumors
Official title: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
Sponsor: MacroGenics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 143.0 (ACTUAL)
Number of arms: 10.0
Start date: 2018-11-21
Primary completion date: 2023-03-18
Completion date: 2023-03-18
Plan to share individual participant data: NO
Clinical trial NCT05525455: TT-816 as Monotherapy or in Combination With a PD-1 Inhibitor in Patients With Advanced Cancers (SEABEAM) (MK3475-E88)
Official title: A Phase 1/2, First-in-human Study of the Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of TT-816 as Monotherapy or in Combination With a PD-1 Inhibitor in Patients With Advanced Cancers (SEABEAM) (MK3475-E88)
Sponsor: Teon Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Company operational decision. Decision to stop study is not due to safety or efficacy concerns.
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-08-29
Primary completion date: 2023-09-07
Completion date: 2023-09-07
Plan to share individual participant data: NO
Clinical trial NCT04228601: A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer
Official title: A Phase Ib/II Study to Assess the Tolerability, Safety and Efficacy of Fluzoparib in Combination With mFOLFIRINOX Followed by Fluzoparib Maintenance Monotherapy in Patients With Advanced Pancreatic Cancer
Sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 39.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-21
Primary completion date: 2022-08-10
Completion date: 2023-01-15
Clinical trial NCT04375202: Colchicine in COVID-19: a Pilot Study
Official title: Treatment With COLchicine of Patients Affected by COVID-19: a Pilot Study
Acronym: COLVID-19
Sponsor: University Of Perugia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Insufficient rate of patient accrual and newly available scientific evidence
Enrollment: 227.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-18
Primary completion date: 2021-10-31
Completion date: 2021-10-31
Plan to share individual participant data: NO
Clinical trial NCT04839549: Efficacy and Safety of Dextenza Compared to Topical Fluorometholone in Patients With Ocular Rosacea
Official title: Randomized, Open Label, Prospective Study on the Efficacy and Safety of Dextenza Compared to Topical Fluorometholone in Patients With Ocular Rosacea (ROSE Study)
Sponsor: Eye Associates of Central Texas (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Lack of patient enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-06
Primary completion date: 2022-11-29
Completion date: 2022-11-29
Plan to share individual participant data: NO
Clinical trial NCT04202497: A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants
Official title: A Phase 1, Open-label, Positron Emission Tomography Study With [18F]MNI-1054 to Determine Lysine-Specific Demethylase 1A Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Subjects
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study was prematurely terminated because of administrative reasons.
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-18
Primary completion date: 2020-03-05
Completion date: 2020-03-19
Baseline population: The safety set included all enrolled participants who received at least 1 dose of \[18F\]MNI-1054 or TAK-418.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT03221842: Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
Official title: A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients
Sponsor: CSL Behring (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was terminated early due to futility of enrolment and not for safety reasons.
Enrollment: 63.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-06
Primary completion date: 2021-01-20
Completion date: 2021-01-20
Limitations and caveats: The Sponsor terminated the study due to futility of enrolment. Because of the study termination, there are limitations in interpreting analyses and efficacy results based on small numbers of subjects. No subject reached the 48-month follow-up endpoint.
Plan to share individual participant data: NO
Clinical trial NCT03166787: Hookah Smoking, Carbon Monoxide, and Coronary Endothelial Function
Official title: Hookah Smoking, Carbon Monoxide, and Coronary Endothelial Function
Sponsor: Cedars-Sinai Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to the Pandemic and the nature of this study we decided to terminate this study.
Enrollment: 60.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-08-15
Primary completion date: 2020-04-15
Completion date: 2020-10-15
Plan to share individual participant data: NO
Clinical trial NCT04577794: A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Ulcerative Colitis
Acronym: SEA TURTLE
Sponsor: Galapagos NV (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-05
Primary completion date: 2021-05-17
Completion date: 2021-05-31
Baseline population: Safety analysis set consisted of all participants who received at least 1 dose of investigational product (IP).
Plan to share individual participant data: NO
Clinical trial NCT03319316: Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
Official title: Randomized Phase II Study of Durvalumab and Tremelimumab Combination Versus Standard of Care Following First-line Platinum Based Chemotherapy in Two Cohorts of Patients With Non Squamous and Squamous Non-small-cell Lung Cancer (NSCLC)
Acronym: SOLUTION
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Interest withdrawn
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-11-01
Primary completion date: 2021-11-30
Completion date: 2022-11-30
Plan to share individual participant data: NO
Clinical trial NCT04141423: Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil
Official title: An Open Label, Multiple Ascending Dose Trial in Patients With T1DM to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin Tregopil and to Evaluate the Postprandial Glucose Control With Different Meal Types in Comparison With Insulin Aspart
Sponsor: Biocon Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Part 1 completed. Part 2 not initiated
Enrollment: 55.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-10-28
Primary completion date: 2021-04-23
Completion date: 2021-04-23
Plan to share individual participant data: NO
Clinical trial NCT04567173: Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19
Official title: A Randomized, Open-Label, Single Center Clinical Trial to Assess the Efficacy and Safety of Convalescent Plasma to Hospitalized Adult COVID-19 Patients as Adjunctive Therapy to Reduce the Need for ICU Admission: Co-CLARITY Trial
Acronym: Co-CLARITY
Sponsor: University of the Philippines (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Limited enrolment (unable to achieve target sample size)
Enrollment: 44.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-21
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Clinical trial NCT04440163: MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age
Official title: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY PARTICIPANTS ≥10 TO <26 YEARS OF AGE
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 2431.0 (ACTUAL)
Number of arms: 8.0
Start date: 2020-06-17
Primary completion date: 2022-07-24
Completion date: 2022-07-24
Baseline population: Safety population included all randomized participants who received at least 1 dose of investigational product and had safety data reported after vaccination. One participant initially randomized to group 3 was excluded from safety population set as the participant received the wrong vaccination (Trumenba + saline).
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04261075: IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
Official title: A Phase 1, First-in-Human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination With Durvalumab ± Oleclumab in Advanced Solid Tumors
Sponsor: MedImmune LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 57.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-03-03
Primary completion date: 2022-06-16
Completion date: 2022-06-16
Plan to share individual participant data: NO
Clinical trial NCT04641273: A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
Official title: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Combined Phase 2a/2b Study to Assess the Efficacy and Safety of BAY 1817080 in Patients With Diabetic Neuropathic Pain
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of efficacy
Enrollment: 154.0 (ACTUAL)
Number of arms: 7.0
Start date: 2021-01-22
Primary completion date: 2021-09-23
Completion date: 2021-10-18
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Clinical trial NCT02028884: Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
Official title: A Multicenter, Randomized, Addition to Baseline Treatment, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 85.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-02-20
Primary completion date: 2018-06-06
Completion date: 2021-12-23
Baseline population: Intent-to-treat (ITT) population included all participants randomized to the treatment groups.
Clinical trial NCT03786380: Diabetic Gastroparesis Study 05
Official title: Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis
Sponsor: Allergan (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The Relamorelin program is being terminated solely based on a business decision.
Enrollment: 202.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-20
Primary completion date: 2020-10-05
Completion date: 2020-10-05
Baseline population: Enrolled Population included all participants enrolled in the study.
Plan to share individual participant data: NO
Clinical trial NCT04081350: A Study of LY3471851 in Participants With Eczema
Official title: A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Sponsor: Nektar Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 48.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-12-04
Primary completion date: 2022-06-24
Completion date: 2022-06-24
Plan to share individual participant data: NO